AXON stock forecast, quote, news & analysis
Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions... Show more
Axon Enterprise (AXON) Stock Analysis: Strong Recurring Revenue Growth Meets a Valuation Reset
Key Takeaways
- AXON shares were essentially flat over the past 30 days, moving roughly +0.3% from a closing level near $424.75 to about $425.87, despite meaningful intraday volatility during the period.
- The flat 30-day move contrasts with a deeper drawdown: the stock remains down roughly 30% year-to-date and about 43% over the past year amid a broader software-sector valuation reset.
- Underlying fundamentals remain robust, with second-quarter 2026 revenue of about $904 million (up roughly 35% year over year), annual recurring revenue near $1.6 billion, and net revenue retention of 126%.
- Key near-term catalysts include the company's third-quarter 2026 earnings report, scheduled for release on November 5, 2026, and continued traction in AI-enabled software and counter-drone offerings.
- Analyst sentiment remains broadly constructive, with a consensus Strong Buy rating and an average price target well above recent trading levels, even as several firms have trimmed individual targets.
- For additional detail on valuation and expectations, explore Axon's Price Targets, Earnings, and Forecast pages.
- Discover actionable, data-driven trading ideas on Tickeron's Trending AI Robots page.
Current Market Snapshot
Axon Enterprise shares traded near $425 in late October 2026, roughly unchanged from a month earlier. The stability of the trailing-30-day window masks a choppier path: the stock declined from the mid-$450s in late September toward the $380s by mid-October before rebounding. That intraday range reflects lingering investor caution rather than a decisive directional move.
The broader context is more telling. Even after recovering from its recent lows, Axon remains well below its 2025 peak and has underperformed a software sector that has largely rebounded in 2026. The company now carries a market capitalization of roughly $34 billion, with a price-to-sales multiple that has compressed sharply from its earlier highs. This combination—solid operating momentum alongside a meaningful de-rating—defines the current narrative for AXON.
Axon Enterprise (AXON) Business Overview and Competitive Position
Axon Enterprise, Inc. is the global leader in public safety technology, serving state, local, federal, and international agencies as well as a growing enterprise market. The company's ecosystem spans hardware and software, anchored by its TASER conducted-energy devices, body-worn and in-car cameras, and the Axon Evidence cloud platform for managing digital evidence.
Axon has expanded well beyond its original device franchise. Its portfolio now includes the AI-enabled Axon Era Plan, generative reporting tools such as Draft One, the Axon Assistant productivity suite, the Fusus real-time crime-center platform, Dedrone counter-drone technology, and emerging 911 solutions. This hardware-plus-software model generates durable, recurring revenue through long-term subscription contracts, which investors follow closely because of its high visibility and compounding growth.
Competitive strengths include deep integration across the public-safety workflow, high customer switching costs, a track record of innovation, and an expanding international and enterprise footprint. Founder-led since 1993, Axon has positioned itself as a mission-critical technology provider where trust, security, and reliability are central to customer adoption.
Recent Developments Driving AXON
Several verified developments shaped Axon's recent trading. In August 2026, the company reported second-quarter revenue of approximately $904 million, up about 35% year over year and ahead of consensus, though non-GAAP earnings per share of $1.88 narrowly missed estimates. Management subsequently raised its full-year revenue outlook to 32%–34% growth while maintaining an adjusted EBITDA margin target of about 25.5%.
Product momentum continued to accelerate. AI product revenue grew more than 700% year over year in the first quarter, and management highlighted rapid adoption of the AI Era Plan alongside strength in Dedrone, which surpassed $100 million in quarterly revenue after supporting U.S. World Cup stadiums. At the 2026 IACP conference, Axon unveiled its Axon Body 5 camera, pairing upgraded AI processing with deeper software integration.
At the same time, sentiment was tempered by valuation and margin concerns. A $1 billion convertible notes offering, a lower cash-flow outlook tied to an investment cycle, and gross-margin pressure from tariffs, memory costs, and product mix all weighed on the shares. Analyst actions reflected this tension: UBS initiated coverage with a Hold rating and a $470 target, while Raymond James and TD Cowen lowered their price targets to $675 and $800, respectively, while maintaining constructive ratings.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page offers a curated view of the platform's most relevant automated strategies. Tickeron hosts hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most pertinent bots are surfaced in this section. Each bot differs in strategy, timeframe, and performance metrics, allowing users to evaluate approaches aligned with their own objectives and risk tolerance. The page serves as a practical starting point for exploring how algorithmic signals can complement traditional research. Visitors can browse the featured bots to see which strategies are currently gaining traction across the market.
2026 Outlook and What Investors Should Watch
Looking ahead, Axon's third-quarter earnings report on November 5, 2026, is the most immediate catalyst. Investors will focus on revenue growth against the company's raised 32%–34% guidance, adjusted EBITDA margins, free-cash-flow conversion, and any update on the full-year outlook. Management has signaled that Q3 could be seasonally soft before a stronger fourth quarter, so commentary on the demand pipeline will be closely scrutinized.
Beyond earnings, key themes include the durability of AI and counter-drone growth, international expansion, and the pace of enterprise adoption. Margin recovery will depend on memory costs, tariff exposure, and product mix, while investor confidence may hinge on the company demonstrating improving cash-flow conversion as it scales newer businesses. Macroeconomic conditions, government budget cycles, and competitive dynamics in public-safety technology remain important external factors. These elements, rather than short-term price swings, will likely shape AXON's trajectory through 2026.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AXON's Indicator enters downward trend
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 115 similar instances where the Aroon Indicator formed such a pattern. In 95 of the 115 cases the stock moved lower. This puts the odds of a downward move at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 49 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense